Accelerating Rare disease Cures Program

The Food and Drug Administration is forecasting a funding opportunity under its Advancing Rare Disease Cures Program to accelerate the development of therapies for rare diseases through strategic partnerships and financial support. This initiative, linked to the Biologics License Application and Prescription Drug User Fee Act frameworks, aims to streamline regulatory pathways and enhance access to innovative treatments for underserved patient populations. The program targets organizations engaged in research, development, and clinical translation of novel therapeutics for rare conditions, with a focus on accelerating timelines and reducing barriers to market entry. The solicitation is classified under NAICS code 541690, indicating a focus on other scientific and technical consulting services, suggesting a collaborative, advisory, and support-oriented approach rather than direct product procurement. The opportunity is posted under the FDA’s Center for Drug Evaluation and Research, with official inquiries directed to the Cder Acquisition Liaison. While a formal solicitation number has not yet been issued, potential applicants are encouraged to monitor the OSDBU portal for updates. The contracting officer position remains vacant, indicating the procurement is in an early, preparatory phase, with anticipated formal release likely in the coming months.